Titan Pharmaceuticals Inc (TTNP)

[Serenity3]

"Higher drug acquisition costs for BSI (+$6,492) were outpaced, primarily by reductions in emergency room/hospital utilization (-$8,040) and criminality (-$1,212)".. While the methodology here was a simulation, reductions in ER visits in the real world I think is understated & is salient to demonstrate economic savings … particularly for insurance companies & HMO's… each ER visit clocks in @ ~ 30 K… Braeburn needs to document research on actual reduction of ER visits in area hospitals that are in the midst of the opioid epidemic to demonstrate efficacy & economic viability of BSI… (yes, I know HIPAA constraints will challenge data gathering.. But study design is key.. even small sample sizes are relevant).. thank you for posting